Patents Examined by Zohreh A. Fay
  • Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10772830
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 15, 2020
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10765718
    Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: September 8, 2020
    Assignee: GOLO LLC
    Inventors: Christopher Brian Lundin, Terry Shirvani
  • Patent number: 10758565
    Abstract: The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Further provided are ACC compositions suitable for buccal or sublingual administration.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: September 1, 2020
    Assignee: AMORPHICAL LTD.
    Inventors: Yosef Ben, Yigal Dov Blum
  • Patent number: 10751337
    Abstract: The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 25, 2020
    Assignees: Ocugen, Inc., THE BOARD OF TRUSTEEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Sandeep Jain, Uday Bhaskar Kompella, Shankar Musunuri
  • Patent number: 10751336
    Abstract: A nicotine powder inhaler (10) comprises a body extending between a mouthpiece portion (12) and a distal end portion (14), an airflow channel (15) extending between the mouthpiece portion and the distal end portion and a nicotine powder receptacle (20) disposed along the airflow channel, and a powder system disposed within the nicotine powder receptacle. The powder system includes a first plurality of particles having a particle size of about (10) micrometres or less and including nicotine and a second plurality of particles having a particle size of about 20 micrometres of greater and including flavour. The first plurality of particles comprise an amino acid or nicotine selected from the group consisting of nicotine pyruvate, nicotine mono-pyruvate, nicotine aspartate and nicotine lactate.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: August 25, 2020
    Assignee: Philip Morris Products S.A.
    Inventor: Gerard Zuber
  • Patent number: 10744135
    Abstract: The present invention belongs, in a general manner to the technological field of the pharmaceutical industry and relates, more specifically, to one or more compositions of second use to be destined for the treatment of melasma. The present invention relates to the use of substances belonging to the group of alpha-adrenergic receptor agonists, in different variable concentrations, for treating conditions of melasma upon human skin. Furthermore, the present invention discloses pharmaceutical compositions, the latter being associated or not with other compounds or methods of treatment, to be utilised for the treatment of melasma.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 18, 2020
    Inventor: Doris Maria Hexsel
  • Patent number: 10736326
    Abstract: Nematode dispersal is one of the key features for success as a biocontrol agent. Currently, commercially available nematodes do not disperse sufficiently when they are applied to a field. Since the insect target is mobile, nematodes need to be actively moving and seeking an insect host. We developed a pheromone extract from nematode growth medium that disperses nematodes. This extract was unstable in liquid form. We have found that the extract can be dried to retain activity during storage or shipment. Exposing nematodes to pheromone extract before they are applied to a field activates them to disperse and seek a new host. This exposure needs to be at least 20 min. When nematodes are actively seeking a new host this increases nematode insect encounter and increases insect mortality leading to increased effectiveness of insect nematodes as biological control agents.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 11, 2020
    Assignee: PHERONYM, INC.
    Inventor: Fatma Kaplan
  • Patent number: 10709786
    Abstract: The present invention provides a stable and clear aqueous liquid preparation containing (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl) oxyacetic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and bensalkonium chloride represented by the formula: [C6H5CH2N(CH3)2R]Cl wherein R is an alkyl group having 8-18 carbon atoms.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: July 14, 2020
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Yuko Shikamura, Yuka Higashimura
  • Patent number: 10702471
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: July 7, 2020
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10695182
    Abstract: Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 30, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Benjamin T. Reves, David S. Scher, Susan J. Drapeau, Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 10695332
    Abstract: The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 30, 2020
    Assignee: NewMarket Pharmaceuticals LLC
    Inventors: Mark Ridall, David Rock
  • Patent number: 10689397
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 23, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10690672
    Abstract: Disclosed herein are methods for treating subjects with breast cancer, comprising determining a therapeutic regimen for cancer by measuring the level (amount) of proteins of one or more biomarkers. Also disclosed are methods of predicting or assessing therapeutic outcome for subject.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: June 23, 2020
    Assignee: George Mason Research Foundation, Inc.
    Inventors: Emanuel Petricoin, Julia Wulfkuhle
  • Patent number: 10675362
    Abstract: A composition, as well as methods using the composition, for detection or quantification of a molecule at a singlet state (e.g., singlet oxygen). The composition includes one or more nanoparticles, and the nanoparticle has an energy donor, an energy acceptor associated with the energy donor, and an energy transfer mechanism between the energy donor and the energy acceptor.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 9, 2020
    Assignee: Trustees of Tufts College
    Inventors: Samuel W. Thomas, III, Fanny Frausto, Jingjing Zhang
  • Patent number: 10675234
    Abstract: The present invention generally relates to skin care and, in particular, to systems and methods for treating and/or preventing acne. Acne is believed to be caused by a combination of factors, including Propionibacterium acnes bacteria, excess sebum production, and inflammation from the immune response (e.g., in response to P. acnes). Certain aspects of the invention are thus directed to one or more compositions that collectively target these factors, although it should be understood that a single composition may target more than one factor at a time. For instance, in one set of embodiments, a treatment may include a first composition that cleans the skin, a second composition that contains growth inhibitor of P. acnes (e.g., for use during the day), and a third composition that inhibits sebum production (e.g., for use during the night). One or more of these may contain other components, such as anti-inflammatory agents, moisturizers, topical anti-microbial agents (e.g., salicylic acid), or the like.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: June 9, 2020
    Assignee: N.V. Perricone LLC
    Inventor: Christopher Cain Caires
  • Patent number: 10675279
    Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 9, 2020
    Assignee: NICOX OPTHALMICS, INC.
    Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
  • Patent number: 10675265
    Abstract: Method of enhancing the bioavailability of a tocotrienol to a human for treating a disease or condition amenable to treatment with a tocotrienol, by administering a composition formulated for transmucosal delivery to the human. The composition contains at least one tocotrienol, and the disease or condition is selected from post-exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy and a condition resulting from radiation exposure.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: June 9, 2020
    Assignee: INVICTUS BIOTECHNOLOGY PTY LTD
    Inventor: Glenn Tong
  • Patent number: 10660963
    Abstract: Disclosed are a pharmaceutical composition comprising tacrolimus and a preparation method thereof.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: May 26, 2020
    Assignee: Hangzhou SoliPharma Co., Ltd.
    Inventors: Xiaoxia Sheng, Yong Tang
  • Patent number: 10660851
    Abstract: A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a sterically hindered nitrone and a sterically hindered amine differing from nitrone with respect to at least one property. A portion of the nitrone included with the formulation and/or amine included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: May 26, 2020
    Assignee: RXOS MEDICAL
    Inventors: Richard Millis, Jeffrey Niezgoda, Rajagopalan Sridhar